CN113774030B - Hybridoma cell strain secreting anti-picloram monoclonal antibody and application thereof - Google Patents
Hybridoma cell strain secreting anti-picloram monoclonal antibody and application thereof Download PDFInfo
- Publication number
- CN113774030B CN113774030B CN202111117099.XA CN202111117099A CN113774030B CN 113774030 B CN113774030 B CN 113774030B CN 202111117099 A CN202111117099 A CN 202111117099A CN 113774030 B CN113774030 B CN 113774030B
- Authority
- CN
- China
- Prior art keywords
- picloram
- monoclonal antibody
- hybridoma cell
- cell strain
- hapten
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000005595 Picloram Substances 0.000 title claims abstract description 78
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 21
- 230000003248 secreting effect Effects 0.000 title claims abstract description 11
- NQQVFXUMIDALNH-UHFFFAOYSA-N picloram Chemical compound NC1=C(Cl)C(Cl)=NC(C(O)=O)=C1Cl NQQVFXUMIDALNH-UHFFFAOYSA-N 0.000 claims abstract description 64
- 238000001514 detection method Methods 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims abstract description 18
- 238000012360 testing method Methods 0.000 claims abstract description 9
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 238000009629 microbiological culture Methods 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 28
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 14
- 230000003053 immunization Effects 0.000 claims description 14
- 238000002649 immunization Methods 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 241000699670 Mus sp. Species 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 8
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 5
- 230000007910 cell fusion Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000005468 Aminopyralid Substances 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 4
- NIXXQNOQHKNPEJ-UHFFFAOYSA-N aminopyralid Chemical compound NC1=CC(Cl)=NC(C(O)=O)=C1Cl NIXXQNOQHKNPEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 230000001804 emulsifying effect Effects 0.000 claims description 4
- BXGTVNLGPMZLAZ-UHFFFAOYSA-N n'-ethylmethanediimine;hydrochloride Chemical compound Cl.CCN=C=N BXGTVNLGPMZLAZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 3
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000528 amlodipine Drugs 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 210000004988 splenocyte Anatomy 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 235000013339 cereals Nutrition 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 235000000346 sugar Nutrition 0.000 abstract description 3
- 235000013311 vegetables Nutrition 0.000 abstract description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 abstract description 2
- 238000003018 immunoassay Methods 0.000 abstract description 2
- 235000019198 oils Nutrition 0.000 abstract description 2
- 241000208125 Nicotiana Species 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 238000000034 method Methods 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000012980 RPMI-1640 medium Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 240000001140 Mimosa pudica Species 0.000 description 1
- 235000016462 Mimosa pudica Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 1
- MUUGCDGGIVCSDT-UHFFFAOYSA-N [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O MUUGCDGGIVCSDT-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000036253 epinasty Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- G01N33/184—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a hybridoma cell strain secreting an anti-picloram monoclonal antibody and application thereof, and belongs to the field of food safety immunodetection. The hybridoma cell strain secreting the anti-picloram monoclonal antibody has been preserved in the China general microbiological culture Collection center of the Committee for culture Collection of microorganisms with the preservation number of CGMCC No. 20794. The monoclonal antibody cell strain of the invention can be used for immunoassay detection, and has good detection sensitivity and specificity (IC) for picloram50The value was 50 ng/mL). The achievement of the invention can use the immunodetection kit for preparing the picloram and the colloidal gold test strip to provide a powerful detection method and means for detecting the residual quantity of the picloram in grains, oil, vegetables, sugar and tobacco.
Description
Technical Field
The invention belongs to the technical field of food safety immunodetection, and particularly relates to a hybridoma cell strain secreting an anti-picloram monoclonal antibody and application thereof.
Background
Picloram is a novel pyridine carboxylic acid herbicide widely used for weed control in mountainous regions, grasslands, planting fields and non-cultivated lands, and is now being researched and developed for weed control in rape and cereal crop fields. The preparation has low toxicity, no teratogenicity, mutagenicity, carcinogenesis, no adverse side effect on endocrine and reproduction, and low toxicity to human. Picloram belongs to a synthetic hormone type herbicide. It can be quickly absorbed by stem, leaf and root of plant, and can induce the plant to produce epinasty reaction in the sensitive plant body so as to make the plant grow and die quickly.
At present, the method for detecting picloram residues is mainly an instrumental analysis method, and comprises a gas chromatography method, a gas chromatography-mass spectrometry tandem method and the like. The methods have reliable results and high sensitivity, and related technical standards are available for reference. However, expensive instruments and special operators are required, and the sample pretreatment is complicated, high in cost and long in time, so that the rapid and simple field detection requirement cannot be better met.
Therefore, the establishment of a rapid and simple picloram detection method is of great significance. An enzyme-linked immunosorbent assay (ELISA) is an extremely high-efficiency, sensitive and rapid detection method, is suitable for the field rapid detection of a large number of samples, and provides a new detection approach for the detection of picloram.
Disclosure of Invention
In order to solve the technical problems, the invention provides a hybridoma cell strain secreting an anti-picloram monoclonal antibody, and a construction method and application thereof. The antibody secreted by the cell strain has higher detection sensitivity for picloram, and can be used for establishing an immunological detection method for picloram. The achievement of the invention can use the immunodetection kit for preparing the picloram and the colloidal gold test strip to provide a powerful detection method and means for detecting the residual quantity of the picloram in grains, oil, vegetables, sugar and tobacco.
A hybridoma cell strain secreting an anti-picloram monoclonal antibody is preserved in China general microbiological culture Collection center at 27.09.2020/27.A preservation address of No. 3 Hospital No. 1 of Beijing, Chaoyang, and a preservation number of CGMCC No. 20794.
A preparation method of a hybridoma cell strain secreting an anti-picloram monoclonal antibody comprises the following steps:
s1: adding Picloram solution to SOCl2Heating and refluxing to form an acidizing solution of picloram, performing solid-liquid separation after the reaction is finished to obtain a solid phase, dissolving the solid phase in an organic solvent to obtain a picloram chlorine solution, uniformly stirring the picloram chlorine solution and a bovine serum albumin BSA (bovine serum albumin) alkaline solution, performing solid-liquid separation after the reaction is finished to obtain a filtrate, and dialyzing the obtained filtrate to obtain a picloram hapten;
s2: mixing and dissolving the picloram hapten, the N-hydroxysuccinimide and the 1-ethyl carbodiimide hydrochloride obtained in the step S1 in an organic solvent, reacting for 6-8 hours to obtain a mixture, adding the picloram hapten into a protein solution, and reacting to obtain a conjugate of the picloram hapten and bovine serum albumin BSA;
s3: mixing and emulsifying the conjugate obtained in S2 and complete Freund 'S adjuvant to obtain immunogen 1, and mixing and emulsifying the conjugate obtained in S2 and incomplete Freund' S adjuvant to obtain immunogen 2;
s4: the immunogen 1 obtained in the S3 is used for subcutaneous immunization of mice, the immunized mice are further boosted by using the immunogen 2 in the S3, and the conjugate of the picloram hapten and the protein in the S2 is used for sprint immunization;
s5: and (3) taking spleen cells and myeloma cells of the immunized mouse punched in S4, and carrying out cell fusion to obtain the hybridoma cell strain.
In one embodiment of the present invention, the picloram in S1: the mol ratio of the thionyl chloride is 1:1.5-1: 2.
in one embodiment of the present invention, the molar ratio of the picloram to the RSA in the picloram solution in S1 is 1:1.5-1: 2.
In one embodiment of the present invention, the alkali in the alkaline solution in S1 is sodium hydroxide or potassium hydroxide.
In one embodiment of the present invention, the protein in the protein solution in S2 is chicken ovalbumin or bovine serum albumin BSA.
In one embodiment of the present invention, the molar ratio of picloram hapten to N-hydroxysuccinimide in S2 is 3:1-4: 1.
In one embodiment of the present invention, the molar ratio of the picloram hapten to the 1-ethylcarbodiimide hydrochloride in S2 is 3:1 to 4: 1.
The hybridoma cell strain is applied to the preparation of the amlodipine acid monoclonal antibody.
The monoclonal antibody against picloram is obtained by secreting the hybridoma cell strain.
The monoclonal antibody against picloram is applied to the detection of picloram drugs.
A method for detecting picloram drugs utilizes the anti-picloram monoclonal antibody to carry out detection.
A kit containing the monoclonal antibody against aminopyralid.
In one embodiment of the invention, the kit is used for detecting picloram.
A test strip comprises the monoclonal antibody against the aminopyralid.
In one embodiment of the invention, the test strip is used for detecting picloram.
Compared with the prior art, the technical scheme of the invention has the following advantages:
the monoclonal antibody secreted by the hybridoma cell strain 1A8 has good specificity and detection sensitivity (IC) on picloram50The value is 50ng/mL), the detection of the residual quantity of the picloram in the grains, the oil, the vegetables and the sugar can be realized, the raw material is provided for the immunological detection of the residual picloram in the food, and the practical application value is realized. The monoclonal antibody has strong specificity, can greatly improve the specificity of antigen-antibody reaction, reduces possible cross reaction, ensures that the reliability of a test result in a detection process is higher, and simultaneously ensures that the uniformity and the biological activity unicity of the monoclonal antibody ensure that the quality of the antigen-antibody reaction result is convenient to control, thereby being beneficial to standardization and normalization.
Drawings
In order that the present disclosure may be more readily and clearly understood, reference is now made to the following detailed description of the embodiments of the present disclosure taken in conjunction with the accompanying drawings, in which
FIG. 1 is a standard curve of the inhibition of picloram by the monoclonal antibody 1A8 of the present invention.
Detailed Description
The present invention is further described below in conjunction with the following figures and specific examples so that those skilled in the art may better understand the present invention and practice it, but the examples are not intended to limit the present invention.
The experimental raw materials adopted by the invention can be purchased from the market or prepared according to the existing method.
Solution preparation:
carbonate Buffer (CBS): weighing Na2CO31.59 g，NaHCO32.93 g, respectively dissolving in a small amount of double distilled water, mixing, adding the double distilled water to about 800mL, uniformly mixing, adjusting the pH value to 9.6, adding the double distilled water to a constant volume of 1000mL, and storing at 4 ℃ for later use.
Phosphate Buffered Saline (PBS): 8.0g NaCl, 0.2g KCl, 0.2g KH2PO4，2.9gNa2HPO4·12H2Dissolving O in 800mL of pure water, adjusting the pH value to 7.2-7.4 by using NaOH or HCl, and fixing the volume to 1000 mL;
washing solution (PBST): adding 0.5mL of Tween-20 into 1000mL of PBS solution with the concentration of 0.01 mol/LpH7.4;
PBST: PBS containing 0.05% Tween-20;
antibody dilution: wash buffer containing 0.1% gelatin;
TMB color development liquid: solution A: na (Na)2HPO4.12H218.43g of O, 9.33g of citric acid and pure water to reach the constant volume of 1000 mL; and B, liquid B: 60mg of TMB was dissolved in 100mL of ethylene glycol. A. Mixing the solution B according to the volume ratio of 1:5 to obtain TMB. The color developing liquid is mixed at present.
Example 1
Preparation of hybridoma cell line 1A8
1. Preparation of complete antigens
(1) Synthesis of hapten, the reaction equation is shown in the following chart:
the derivation procedure is briefly as follows:
1. preparation of picloram hapten:
picloram (50mg) was treated with 5mL of thionyl chloride (SOCI)2) Dissolved in a small flask. The solution was refluxed at 85 ℃ for 2.5h to form an acidified solution of picloram. Excess chloride was removed on a rotary evaporator under vacuum at 60 ℃ and the residue was dissolved in 2mL of Tetrahydrofuran (THF). Mixing the picloram chloride solution with 200mg bovine serum albumin BSA in 10mL 0.02M NaOH solutionSlowly stirring. An insoluble precipitate formed after stirring for 18 hours at room temperature before the addition of the acid chloride solution was complete. The reaction mixture was diluted to 200mL with 0.02M NaOH solution, successfully dissolving most of the precipitate. The resulting suspension was centrifuged to remove any precipitate. The supernatant was dialyzed against cold flowing tap water for 24h and lyophilized.
2. Preparation of coating antigen:
weighing 2.9mg of prepared picloram hapten, dissolving in 200 microliter of DMF, slowly stirring, sequentially adding 4.5mg of N-hydroxysuccinimide and 5.4mg of 1-ethyl carbodiimide hydrochloride, and reacting at room temperature for 6-8h to obtain a mixture; then weighing 10mg of chicken ovalbumin OVA, dissolving in 2mL of carbonate buffer solution, slowly dropping the obtained mixture into the chicken ovalbumin solution, reacting for 14h at room temperature under stirring, dialyzing for 3d by 0.01mol/L phosphate buffer PBS to obtain the conjugate of picloram-OVA, and freezing and storing at-20 ℃ for later use.
3. Immunization of mice: healthy BALB/c mice 6-8 weeks old were selected for immunization. After the complete antigen of the picloram is mixed and emulsified with the same amount of Freund's adjuvant, BALB/c mice are immunized respectively through back subcutaneous injection. Complete Freund's adjuvant was used for the first immunization, followed by incomplete Freund's adjuvant. The interval between the first immunization and the second boosting immunization is 28 days, and the interval between the boosting immunization is 21 days. Blood was collected 7 days after the third immunization (mice were bled with tail-off 5 μ L +995 μ L antibody diluent ═ antiserum), serum titers and inhibition were determined in mice using ic-ELISA, mice with high titers and good inhibition were selected, immunized by puncture 21 days after the fifth immunization, injected intraperitoneally, requiring a halved priming dose without any adjuvant.
4. Cell fusion: after three days of the spurting immunization, cell fusion is carried out according to a conventional PEG (polyethylene glycol, molecular weight is 4000) method, and the specific steps are as follows:
(1) taking eyeballs and blood, immediately putting the mice into 75% alcohol for disinfection after the mice are killed by a cervical vertebra dislocation method, soaking for about 5min, taking out the spleen of the mice by aseptic operation, properly grinding the spleen by using a rubber head of an injector, passing through a 200-mesh cell screen to obtain a spleen cell suspension, collecting, centrifuging (1200rpm, 8min), washing the spleen cells for three times by using an RPMI-1640 culture medium, diluting the spleen cells to a certain volume after the last centrifugation, and counting for later use;
(2) collecting mouse myeloma SP2/0 cells: 7-10 days before fusion, SP2/0 tumor cells were cultured in RPMI-1640 medium containing 10% FBS (fetal bovine serum) at 5% CO2An incubator. Before fusion, the number of SP2/0 tumor cells is required to reach 1-4 multiplied by 107Ensuring that SP2/0 tumor cells are in logarithmic growth phase before fusion. During fusion, tumor cells are collected and suspended in RPMI-1640 basic culture solution for cell counting;
(3) the fusion process is 7 min. 1min, 1mL of PEG 1500 is added to the cells in a dropwise manner from slow to fast; standing for 2 min. Dropping 1mL of RPMI-1640 culture medium within 1min at 3min and 4 min; dropping 2mL of RPMI-1640 culture medium within 1min at 5min and 6 min; at 7min, 1mL of RPMI-1640 medium was added dropwise every 10 s. Then, the mixture is incubated at 37 ℃ for 5min. After centrifugation (800rpm, 8min), the supernatant was discarded and resuspended in RPMI-1640 screening medium containing 20% fetal bovine serum and 2% 50 XHAT, 200. mu.L/well of the medium was applied to a 96-well cell plate and cultured in a 5% CO2 incubator at 37 ℃.
5. Cell screening and cell strain establishment: on day 3 of cell fusion, the fused cells were subjected to RPMI-1640 screening medium half-replacement, on day 5, to total-replacement with RPMI-1640 medium containing 20% fetal bovine serum and 1% 100 XHT, and on day 7, cell supernatants were collected for screening. The screening is divided into two steps: firstly, screening out positive cell holes by using ic-ELISA, and secondly, selecting picloram as a standard substance and measuring the inhibition effect of the positive cells by using the ic-ELISA. And selecting cell pores which have better inhibition on the picloram standard, carrying out subcloning by adopting a limiting dilution method, and carrying out detection by using the same method. This was repeated three times to obtain cell line 1A 8.
6. Preparation and identification of monoclonal antibody: taking BALB/c mice 8-10 weeks old, and injecting 1mL of sterile paraffin oil into the abdominal cavity of each mouse; 7 days later, each mouse was injected intraperitoneally with 1X 106Hybridoma cells, ascites fluid was collected from the seventh day, and the ascites fluid was purified by the octanoic acid-ammonium sulfate method. Under the condition of partial acid, caprylic acid can precipitate other hybrid proteins except IgG immunoglobulin in ascites, and then is separatedRemoving the precipitate; then, the IgG type monoclonal antibody is precipitated by an ammonium sulfate solution of the same saturation, centrifuged, the supernatant is discarded, dissolved by a 0.01MPBS solution (pH 7.4), dialyzed and desalted, and finally the purified monoclonal antibody is stored at-20 ℃.
Determination of IC of monoclonal antibody against Picloram Using Indirect competitive ELISA5050ng/mL, and IC for picloram and the like was verified50And the cross-reactivity ratio are shown in Table 1.
TABLE 1 IC of monoclonal antibody 1A8 for Picloram, Picloram50And cross reaction rate
7. The application of the antibody comprises the following steps: the monoclonal antibody prepared from the hybridoma cell strain 1A8 through ascites in vivo is applied to an addition recovery test of picloram, and the method comprises the following specific steps:
(1) coating: the coated amlodipine acid-OVA was diluted at a rate of 1. mu.g/mL in 0.05M carbonate buffer pH 9.6, and reacted at 37 ℃ for 2 hours at 100. mu.L/well.
(2) Washing: the plate solution was decanted and washed 3 times for 3min each with washing solution.
(3) And (3) sealing: after patting to dryness, 200. mu.L/well blocking solution was added and reacted at 37 ℃ for 2 hours. And drying after washing for later use.
(4) Sample adding: diluting antiserum (which is obtained by diluting the antiserum by a corresponding multiple with an antibody diluent after tail-cutting blood collection of a mouse) from 1:1000 by multiple, adding the diluted antiserum into coated holes of each dilution, reacting at the temperature of 100 mu L/hole for 30 min; after washing sufficiently, HRP-goat anti-mouse IgG diluted at a ratio of 1:3000 was added thereto at 100. mu.L/well, and the reaction was carried out at 37 ℃ for 30 min.
(5) Color development: the ELISA plate was removed, washed thoroughly, and 100. mu.L of TMB developing solution was added to each well, and the reaction was carried out at 37 ℃ in the dark for 15min.
(6) Termination and measurement: the reaction was stopped by adding 50. mu.L of a stop solution to each well, and the OD of each well was measured by a microplate reader450The value is obtained.
Determination of IC of monoclonal antibody to Picloram by IC-ELISA50The concentration is 50ng/mL, which shows that the sensitivity to picloram is good, and the method can be used for the immunoassay detection of picloram. The standard curve of the inhibition of picloram by the monoclonal antibody 1A8 obtained in this example is shown in fig. 1.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications of the invention may be made without departing from the scope of the invention.
Claims (9)
1. A hybridoma cell strain secreting an amlodipine acid-resistant monoclonal antibody is characterized in that the hybridoma cell strain is preserved in China general microbiological culture Collection center at 09 months and 27 days in 2020, with the preservation address of No. 3 Xilu No. 1 Beijing of the Chaoyang district in Beijing, and the preservation number is CGMCC No. 20794.
2. A preparation method of a hybridoma cell strain secreting an anti-picloram monoclonal antibody is characterized by comprising the following steps:
s1: adding an picloram acid solution into thionyl chloride, heating and refluxing to form an acidizing solution of picloram, performing solid-liquid separation after the reaction is finished, taking a solid phase, dissolving the solid phase in an organic solvent to obtain a picloram chlorine solution, uniformly stirring the picloram chlorine solution and an alkaline solution of bovine serum albumin BSA (bovine serum albumin), performing solid-liquid separation after the reaction is finished, and taking a filtrate to obtain a picloram hapten;
s2: mixing and dissolving the obtained picloram hapten, N-hydroxysuccinimide and 1-ethyl carbodiimide hydrochloride in the S1 in an organic solvent, reacting to obtain a mixture, and adding the picloram hapten into a bovine serum albumin solution for reacting to obtain a conjugate of the picloram hapten and the bovine serum albumin;
s3: mixing and emulsifying the conjugate obtained in S2 and complete Freund 'S adjuvant to obtain immunogen 1, and mixing and emulsifying the conjugate obtained in S2 and incomplete Freund' S adjuvant to obtain immunogen 2;
s4: the immunogen 1 obtained in the S3 is used for subcutaneous immunization of a mouse, the immunized mouse is further boosted by using the immunogen 2 in the S3, and the conjugate of the picloram hapten and bovine serum albumin in the S2 is used for sprint immunization;
s5: taking splenocytes and myeloma cells of the mice which are subjected to the sprint immunization in S4, and carrying out cell fusion to obtain the hybridoma cell strain; the structural formula of the picloram hapten in S1 is as follows:
3. the hybridoma cell strain of claim 1, wherein the hybridoma cell strain is used for preparing an anti-picloram monoclonal antibody.
4. An anti-picloram monoclonal antibody, wherein the anti-picloram monoclonal antibody is secreted by the hybridoma cell line of claim 1.
5. The use of the monoclonal antibody against picloram according to claim 4 for the analytical detection of picloram.
6. A kit comprising the monoclonal antibody against aminopyralid according to claim 4.
7. The kit of claim 6, wherein the kit is for detecting picloram.
8. A test strip comprising the monoclonal antibody against aminopyralid of claim 4.
9. The test strip of claim 8, wherein the test strip is for detecting picloram.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111117099.XA CN113774030B (en) | 2021-09-23 | 2021-09-23 | Hybridoma cell strain secreting anti-picloram monoclonal antibody and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111117099.XA CN113774030B (en) | 2021-09-23 | 2021-09-23 | Hybridoma cell strain secreting anti-picloram monoclonal antibody and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113774030A CN113774030A (en) | 2021-12-10 |
| CN113774030B true CN113774030B (en) | 2022-05-24 |
Family
ID=78852812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111117099.XA Active CN113774030B (en) | 2021-09-23 | 2021-09-23 | Hybridoma cell strain secreting anti-picloram monoclonal antibody and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113774030B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114774368B (en) * | 2022-05-16 | 2023-06-06 | 江南大学 | Hybridoma cell strain secreting anti-flumioxazin monoclonal antibody and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101412673A (en) * | 2008-11-25 | 2009-04-22 | 南京农业大学 | Deltamethrin antigen and antibody, as well as use thereof |
| CN101433825A (en) * | 2008-12-03 | 2009-05-20 | 中国农业大学 | Method for extracting salinomycin compound from animal sample and special immune affinity sorbent thereof |
| CN102516148A (en) * | 2011-11-23 | 2012-06-27 | 华南农业大学 | Half antigen and antigen of tenuazonic acid and preparation method and application thereof |
| CA2815847A1 (en) * | 2012-09-18 | 2014-03-18 | University Of Guelph | Vectors and methods for enhancing recombinant protein expression in plants |
| CN112375744A (en) * | 2020-12-04 | 2021-02-19 | 江南大学 | Dihydropyridine monoclonal antibody hybridoma cell strain and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108424880A (en) * | 2018-03-16 | 2018-08-21 | 江南大学 | A kind of hybridoma cell strain and preparation method of secretion cyproheptadine monoclonal antibody |
-
2021
- 2021-09-23 CN CN202111117099.XA patent/CN113774030B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101412673A (en) * | 2008-11-25 | 2009-04-22 | 南京农业大学 | Deltamethrin antigen and antibody, as well as use thereof |
| CN101433825A (en) * | 2008-12-03 | 2009-05-20 | 中国农业大学 | Method for extracting salinomycin compound from animal sample and special immune affinity sorbent thereof |
| CN102516148A (en) * | 2011-11-23 | 2012-06-27 | 华南农业大学 | Half antigen and antigen of tenuazonic acid and preparation method and application thereof |
| CA2815847A1 (en) * | 2012-09-18 | 2014-03-18 | University Of Guelph | Vectors and methods for enhancing recombinant protein expression in plants |
| CN112375744A (en) * | 2020-12-04 | 2021-02-19 | 江南大学 | Dihydropyridine monoclonal antibody hybridoma cell strain and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| Rapid Detection of Picloram in Agricultural Field Samples Using a Disposable Immunomembrane-Based Electrochemical Sensor;LIN TANG 等;《Environ. Sci. Technol.》;20081231;摘要以及1208页材料和方法 * |
| 间接竞争ELISA法测定稻田土壤中除草剂毒莠定的残留量;黎媛萍等;《环境科学学报》;20070715(第07期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113774030A (en) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111304174A (en) | Triazolone monoclonal antibody hybridoma cell strain B11S and application thereof | |
| CN108251381B (en) | Paraquat monoclonal antibody hybridoma cell strain and application thereof | |
| CN113736744A (en) | Digitalis glycosides monoclonal antibody hybridoma cell strain and application thereof | |
| CN107119022B (en) | Isobacteriumurea monoclonal antibody hybridoma cell strain ZXL-2 and application thereof | |
| CN112877296A (en) | Anti-phenacetin monoclonal antibody hybridoma cell strain AD and preparation method and application thereof | |
| CN113774030B (en) | Hybridoma cell strain secreting anti-picloram monoclonal antibody and application thereof | |
| CN110950962B (en) | Hybridoma cell strain A11S for secreting bimesomepheniul monoclonal antibody and application thereof | |
| CN110713986B (en) | Vitamin B strain 1 Monoclonal antibody hybridoma cell strain CBDD and application thereof | |
| CN111334479A (en) | Chlorhydroxypyridine monoclonal antibody hybridoma cell strain TYL and application thereof | |
| CN111763658A (en) | Hybridoma cell strain secreting anti-dinitrotolamine monoclonal antibody and application thereof | |
| CN112574957B (en) | Hybridoma cell strain secreting clomazone monoclonal antibody and application thereof | |
| CN114836387A (en) | 11-alpha hydroxyprogesterone monoclonal antibody hybridoma cell strain and application thereof | |
| CN114058594B (en) | Hybridoma cell strain secreting vitamin A monoclonal antibody and application thereof | |
| CN106929479B (en) | Vitamin B2 monoclonal antibody hybridoma cell strain GZ-4 and application thereof | |
| CN111748528B (en) | Hybridoma cell strain secreting monoclonal antibody against fipronil and metabolite thereof and application of hybridoma cell strain | |
| CN112266901B (en) | Azoxystrobin monoclonal antibody hybridoma cell strain and application thereof | |
| CN111454912B (en) | Cyperazine monoclonal antibody hybridoma cell strain and application thereof | |
| CN114181911A (en) | Hybridoma cell strain secreting spironolactone and metabolite monoclonal antibody thereof and application of hybridoma cell strain | |
| CN113897338B (en) | Hybridoma cell strain secreting 2,4-D monoclonal antibody and application thereof | |
| CN114774368B (en) | Hybridoma cell strain secreting anti-flumioxazin monoclonal antibody and application thereof | |
| CN108410824B (en) | Azepinone monoclonal antibody hybridoma cell strain and application thereof | |
| CN114317450B (en) | Hybridoma cell strain secreting Flurobendiamide monoclonal antibody and application thereof | |
| CN112813036B (en) | Triamcinolone acetonide monoclonal antibody hybridoma cell strain and application thereof | |
| CN114908059B (en) | Bispyribac-sodium monoclonal antibody hybridoma cell strain and application thereof | |
| CN113502272B (en) | Amaranth and carmine monoclonal antibody hybridoma cell strain and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |